Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7223295
Reference Type
Journal Article
Subtype
Review
Title
Covalent inhibitors design and discovery
Author(s)
De Cesco, S; Kurian, J; Dufresne, C; Mittermaier, AK; Moitessier, N; ,
Year
2017
Is Peer Reviewed?
Yes
Journal
European Journal of Medicinal Chemistry
ISSN:
0223-5234
EISSN:
1768-3254
Publisher
Elsevier Masson s.r.l.
Volume
138
Page Numbers
96-114
Language
English
PMID
28651155
DOI
10.1016/j.ejmech.2017.06.019
Web of Science Id
WOS:000411297000009
Abstract
In the history of therapeutics, covalent drugs occupy a very distinct category. While representing a significant fraction of the drugs on the market, very few have been deliberately designed to interact covalently with their biological target. In this review, the prevalence of covalent drugs will first be briefly covered, followed by an introduction to their mechanisms of action and more detailed discussions of their discovery and the development of safe and efficient covalent enzyme inhibitors. All stages of a drug discovery program will be covered, from target considerations to lead optimization, strategies to tune reactivity and computational methods. The goal of this article is to provide an overview of the field and to outline good practices that are needed for the proper assessment and development of covalent inhibitors as well as a good understanding of the potential and limitations of current computational methods for the design of covalent drugs.
Keywords
Binding kinetics; Covalent drugs; Docking; Drug design; acetylsalicylic acid; afatinib; azinomycin a; boceprevir; bortezomib; carfilzomib; chlormethine; clopidogrel; covalent inhibitor; enzyme inhibitor; esomeprazole; etacrynic acid; fosfomycin; functional group; lansoprazole; microcystin LR; natural product; odanacatib; penicillin G; rivastigmine; salinosporamide A; saxagliptin; showdomycin; telaprevir; tetrahydrolipstatin; unclassified drug; biological product; covalent bond; drug binding; drug design; drug mechanism; drug structure; kinetic parameters; protein analysis; quantum mechanics; Review; chemistry; drug development; human; kinetics; quantum theory; synthesis; Biological Products; Drug Discovery; Humans; Kinetics; Quantum Theory
Tags
Other
•
Harmful Algal Blooms- Health Effects
April 2021 Literature Search
Scopus
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity